Clinical Trials Logo
  1. Home
  2. Genital Herpes
  3. NCT01390805
  4. Details
NCT01390805 Clinical Trial

Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)

Genital Herpes Clinical Trial

Official title:
Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01390805
Other study ID # 112319
Secondary ID
Status Completed
Phase N/A
First received July 7, 2011
Last updated May 15, 2017
Start date November 2006
Est. completion date March 2011

Study information
Verified date May 2017
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to collect and assess information on proper use of valaciclovir regarding safety and efficacy of long-term use in suppressive therapy for subjects with recurrent genital herpes.

Recruitment information / eligibility
Status Completed
Enrollment 462
Est. completion date March 2011
Est. primary completion date April 2009
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Subjects who started suppressive therapy for recurrent genital herpes for the first time

Exclusion Criteria:

- Subjects with a history of hypersensitivity to the ingredients of VALTREX or aciclovir

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Valaciclovir Hydrochloride.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
GlaxoSmithKline

Outcome
Type Measure Description Time frame Safety issue
Primary The number of adverse events in Japanese subjects with recurrent genital herpes treated with valaciclovir 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06033261 - A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes Phase 1/Phase 2
Completed NCT01132716 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions N/A
Completed NCT01132729 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions N/A
Completed NCT00362297 - Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2 Phase 4
Completed NCT03831165 - Melatonin Effects on Genital Herpes in Brazilian Women Phase 4
Terminated NCT01658826 - Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes Phase 2
Completed NCT00262106 - Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection Phase 3
Completed NCT01346475 - Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2 Phase 4
Terminated NCT03146403 - Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection Phase 2
Completed NCT03080961 - The VIBLOK SAfety and perFormancE Trial N/A
Completed NCT00306787 - Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes Phase 3
Completed NCT00231049 - Trial Evaluating Safety, Tolerability and Immune Response of AG-707 Phase 1
Completed NCT00495573 - HSV-2 Shedding Resolution After Acyclovir Treatment N/A
Completed NCT00477334 - Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients Phase 4
Not yet recruiting NCT03595995 - A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 Phase 2
Completed NCT01281007 - Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes Phase 3
Completed NCT01112956 - Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2 N/A
Completed NCT00129818 - A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding Phase 4
Completed NCT00808405 - GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women N/A
Terminated NCT00495716 - Effect of HSV-2 Suppressive Therapy on Sexual Behavior Phase 4